Latest Radiopharmacology Stories

PRINCETON, N.J., Jan. 14, 2011 /PRNewswire/ -- GE Healthcare announced today the US Food and Drug Administration (FDA) has approved DaTscan(TM) (Ioflupane I 123 Injection), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes (PS).(1) The first FDA-approved diagnostic imaging agent to help physicians evaluate...

PlanClear, the nuclear medicine industry's premier Growth Management firm, has finalized and issued its performance report for the 2010 3rd Qtr and (partial) 4th Qtr accomplishments of industry leader Positron (POSC). The PlanClear report highlighted the accomplishment of three critical benchmarks: 1) Sale of 15 PET Camera systems within one year after receiving FDA approval, 2) Eliminating debt and strengthening the POSC balance sheet, and 3) Successful R&D efforts resulting in a new...

TORONTO, Nov. 17, 2010 /PRNewswire/ -- Millennium Research Group (MRG), the global authority on medical technology market intelligence, has released its latest imaging research data on diagnostic imaging, X-ray, radiopharmaceuticals, and contrast agent markets. MRG's X-ray reports cover cardiovascular X-ray systems such as cardiology and peripheral vascular X-ray systems, general radiography systems, surgical X-ray systems, fluoroscopy systems, and analog and digital mobile radiography...

INDIANAPOLIS and PHILADELPHIA, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. Avid's lead program in development is florbetapir F 18 (18F-AV-45), a molecular imaging agent under investigation for detecting the presence of...

LANGHORNE, Pennsylvania and OXFORD, England, November 3, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy. The data also show that PROSTASCINT images can be a significant predictor...

ROCHESTER, N.Y., Sept. 7 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced it has entered into a scientific collaboration, specific to molecular imaging, with ABX-CRO, a Dresden, Germany based full-service contract research organization. The collaboration joins two of the scientific pioneers in the use of advanced imaging for the clinical study of drugs and medical devices. This partnership will...

The next generation of imaging techniques could harness a technology that moves faster than the speed of lightA study published in the July issue of The Journal of Nuclear Medicine (JNM) reports on investigative research of a novel optical imaging technique called "Cerenkov luminescence imaging (CLI)." According to the authors, the technique could lead to the faster and more cost-effective development of radiopharmaceuticals for the diagnosis and treatment of cancer and other conditions."The...

Collaboration will Assess New and Innovative Imaging Agents for Cancer Detection OTTAWA, June 24 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics. The project, which...

GARDEN GROVE, Calif., June 22 /PRNewswire/ -- Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body. "We are extremely pleased with this opportunity," said Mr. Ngo, President...

Studies use radiation luminescence and radioactive optical nano-imaging techniques indicating tumors and other disease processesDuring SNM's 57th Annual Meeting, investigators presented the results of a multidisciplinary study involving the capture of radiation luminescence and radioactive-excited nanoparticles to help detect subtle signs of disease. Currently, nuclear medicine agents and imaging technology image the behavior of particles at the cellular, molecular and atomic levels, but...